Effect of RAS inhibition on TGF-β, renal function and structure in experimentally induced diabetic hypertensive nephropathy rats

Biomedicine and Pharmacotherapy

Volumn 67, Issue 3, 2013, Pages 209-214

  Mohamed, R H ^a   Abdel Aziz, H R ^b   Abd El Motteleb, D M ^a   Abd El Aziz, T A ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Diabetic hypertensive rat; Fibrosis; RAS; TGF

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; MOEXPRIL; RAS PROTEIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; DRUG THERAPY, COMBINATION; HYPERTENSION, RENAL; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NEPHRITIS; RANDOM ALLOCATION; RAS PROTEINS; RATS; RATS, WISTAR; SPIRONOLACTONE; TETRAHYDROISOQUINOLINES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84875505526     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.08.002     Document Type: Article

References (41)

1. Roberts A.B., Sporn M.B. Transforming growth factor b. Adv Cancer Res 1988, 51:107-145.
2. Ando T., Okuda S., Tamaki K., Yoshitomi K., Fujishima M. Localization of transforming growth factor-β and latent transforming growth factor-β binding protein in rat kidney. Kidney Int 1995, 47:733-739.
3. Border W.A., Noble N.A. Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis. Hypertension 1998, 31:181-188.
4. Gonzalez A., Lopez B., Diez G. Fibrosis in hypertensive heart disease: role of renin - Angiotensin-Aldosterone system. Med Clin North Am 2004, 88:83-97.
5. Reeves W.B., Andreoli T.E. Transforming growth factor b contributes to progressive diabetic nephropathy. PNAS 2000, 97(14):7667-7669.
6. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., et al. Expression of transforming growth factor β isoforms in human glomerular diseases. Kidney Int 1996, 49:461-469.
7. Yu H.C., Burrell L.M., Black M.J., Wu L.L., Dilley R.J., Cooper M.E., et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998, 98:2621-2628.
8. Erman A., Veksler S., Gafter U., Boner G. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. JRAAS 2004, 5:146-151.
9. Juknevicius I., Segal Y., Kren S., Lee R., Hostetter T.H. Effect of aldosterone on renal transforming growth factor-β. Am J Physiol Renal Physiol 2004, 286:F1059-F1062.
10. Navaneethan S.D., Nigwekar S.U., Sehgal A.R., Strippoli G.F.M. Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Clin J Am Soc Nephrol 2009, 4:542-551.
11. Bagrov Y.Y., Manusova N.B., Egorova I.A., Fedorova O.V. Endogenous digitalis-like ligands and Na/K-ATPase inhibition in experimental diabetes mellitus. Front Biosci 2005, 10:2257-2262.
12. Dohl L.K., Knudsen K.D., Heine M.A., Leitl G.J. Effects of Chronic Excess Salt Ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res 1968, 22:11-18.
13. Virdis A., Neves M.F., Amiri F. Spironolactone improves angiotensin - induced vascular changes and oxidative stress. Hypertension 2002, 40(4):504-510.
14. Edling O., BaoG, Feelisch M. Moexipril, a new angiotensin - converting enzyme inhibitor: Pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther 1995, 275(2):854-863.
15. Gosh M.N., Schild H.Q. Anaesthetics used in the laboratory animals in fundamentals of experimental pharmacology 1971, Scientific book agency, Calcuta, 14.
16. Burden D., Blader L., Natoff I. Simple method for recording left ventricular pressure and heart rate in cat. Pharmacol Ther 1979, 5:99.
17. Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J Clin Pathol 1969, 22:246.
18. Henry R.J. Clinical Chemistry, Principle and Technics 1974, Harper and Row, pp. 525. 2nd Edition.
19. Kim S., Romeo D., Yoo Y., Park K. Transforming growth factor-beta: expression in normal and pathological conditions. Horm Res 1994, 42:5-8.
20. Hurst P., Lovell S. Optimized assay for serum angiotensin convering enzyme activity. Clin Chem 1981, 27:2048-2052.
21. Miller W. The molecular biology of steroid hormone synthesis. Endocrinol Rev 1988, 9:295-318.
22. Masseroli M., O'Valle F., Andújar M., Ramírez C., Gómez-Morales M., de Dios Luna J., et al. Design and validation of a new image analysis method for automatic quantification of interstitial fibrosis and glomerular morphometry. Lab Invest 1998, 78:511-522.
23. Border W.A., Noble N.A. Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
24. Nicholas S.B. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol 2003, 49:1319-1325.
25. Kalenderl B., öztürk M., Tunçdemir M., Uysal O. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem 2002, 104(2):123-130.
26. Wang S.N., Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 2000, 278:F554-F560.
27. Johnson R.J., Schreiner G.F. Hypothesis the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997, 52:1169-1179.
28. Kalantarinia K., Okusa M.D. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diab Rep 2006, 6(1):8-16.
29. Noble N.A., Border W.A. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target?. Semin Nephrol 1997, 5:455-456.
30. Riser B., Ladson-Wofford S., Sharba A., Cortes P. TGF-b receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 1999, 56:428-439.
31. Wolf G., Ziyadeh F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999, 56(2):393-405.
32. 2 receptor expression and TGF response to U 26, 619. Am J Physiol 1997, 273:F976-F983.
33. Bertoluci M.C., Uebel D., Schmidt A., Thomazelli F.C.S., Oliveira F.R., Schmid H. Urinary TGF-b1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract 2006, 72:258-264.
34. Fujisawa G., Okada K., Muto S., Fujita N., Itabashi N., Kusano E., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66:1493-1502.
35. Campese V.M., Park J. Use of antagonists of aldosterone in patients with chronic kidney disease: potential advantages and risks. J Hypertens 2006, 24:2157-2159.
36. Shimamoto K., Ura N., Nakagawa M., Higashiura: The mechanisms of improvement of insulin sensitivity by ACEi. Clin Exp Hypertens 1996, 18(2):257-266.
37. Houlihan C.A., Akdeniz A., Tsalamandris C., Cooper M.E., Jerums G., Gilbert R.E. Urinary Transforming Growth Factor-{beta} Excretion in Patients With Hypertension. Type 2 Diabetes, and Elevated Albumin Excretion Rate: Effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002, 25:1072-1077.
38. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936-1939.
39. Sharma K., Eltayeb B.O., McGowan T.A., Dunn S.R., Alzahabi B., Rohde R., et al. Captopril induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin dependent diabetic patients. Am J Kidney Dis 1999, 34:818-823.
40. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.
41. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.